GlassScriptPrepare for your visit
Amol Mittal
Nephrology (Internal Medicine) · Providence, RI · NPI 1033466560
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$2,936.81
in general payments reported to CMS, 2019-2025 · $451 in 2025
The $451 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Who reported paying
General payments only, top 6 by amount.
- Amgen INC. $669.21
- Alexion Pharmaceuticals, INC. $585.05
- Astrazeneca Pharmaceuticals LP $351.45
- Apellis Pharmaceuticals, INC. $327.70
- Travere Therapeutics, INC. $277.67
- Ardelyx, INC. $261.74
Drugs and devices associated with these payments
Xphozah 30 Mg Parsabiv Farxiga Tavneos Rayaldee Lokelma Ultomiris Krystexxa Tarpeyo Aranesp Lupkynis
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Amol Mittal listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/1161542/amol-mittal